Atlas Trials

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Clinical trial NCT06855095 · RECRUITING

Trial details

NCT number
NCT06855095
Sponsor
The Netherlands Cancer Institute
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Neoplasm
Start date
2024-06-25
Primary completion
2027-01-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.